Clearmind Medicine Files Q3 Financials
Ticker: CMND · Form: 6-K · Filed: Mar 19, 2024 · CIK: 1892500
Sentiment: neutral
Topics: financials, foreign-private-issuer, sec-filing
TL;DR
Clearmind Medicine dropped Q3 financials, check 'em out.
AI Summary
Clearmind Medicine Inc. filed its unaudited condensed interim consolidated financial statements and Management's Discussion and Analysis for the three months ended January 31, 2024, on March 18, 2024. The company is incorporated in Z4 and its fiscal year ends on October 31. The filing was made with the Canadian Securities Administration and the Ontario Securities Commission.
Why It Matters
This filing provides investors with an update on Clearmind Medicine's financial performance and operational status for the recent quarter, crucial for assessing the company's trajectory.
Risk Assessment
Risk Level: medium — As a foreign private issuer with a fiscal year end in October and recent filings, the company's financial health and operational updates are key indicators of potential volatility.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Filer of the report
- January 31, 2024 (date) — End of reporting period for financial statements
- March 18, 2024 (date) — Date of filing
- Canadian Securities Administration (company) — Recipient of the filing
- Ontario Securities Commission (company) — Recipient of the filing
FAQ
What period do the unaudited condensed interim consolidated financial statements cover?
The financial statements cover the three months ended January 31, 2024.
When were these financial statements filed?
The financial statements were filed on March 18, 2024.
Which regulatory bodies received this filing?
The filing was made with the Canadian Securities Administration and the Ontario Securities Commission.
What is Clearmind Medicine Inc.'s fiscal year end?
Clearmind Medicine Inc.'s fiscal year ends on October 31.
What type of report is this filing?
This filing is a Report of Foreign Private Issuer on Form 6-K.
Filing Stats: 222 words · 1 min read · ~1 pages · Grade level 12.5 · Accepted 2024-03-18 17:42:18
Filing Documents
- ea0200890-6k_clear.htm (6-K) — 17KB
- ea0200890ex99-1_clear.htm (EX-99.1) — 503KB
- ea0200890ex99-2_clear.htm (EX-99.2) — 149KB
- 0001213900-24-023611.txt ( ) — 4112KB
- cmnd-20240131.xsd (EX-101.SCH) — 83KB
- cmnd-20240131_cal.xml (EX-101.CAL) — 28KB
- cmnd-20240131_def.xml (EX-101.DEF) — 232KB
- cmnd-20240131_lab.xml (EX-101.LAB) — 462KB
- cmnd-20240131_pre.xml (EX-101.PRE) — 243KB
- ea0200890-6k_clear_htm.xml (XML) — 524KB
Management's Discussion and Analysis for the for the three months ended January 31, 2024
Management's Discussion and Analysis for the for the three months ended January 31, 2024. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine Inc. Date: March 18, 2024 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3